News Center
Details
Yichang Renfu Pharmaceutical’s Ursodeoxycholic Acid Capsules Have Been Approved for Market Launch.
Release time:
2024-12-25 08:47
Source:
Recently, Yichang Renfu Pharmaceutical’s Ursodeoxycholic Acid Capsules received the “Drug Registration Certificate” approved and issued by the National Medical Products Administration. This product was approved for marketing under Category 4 of chemical drugs and is deemed to have passed the consistency evaluation.
Ursodeoxycholic acid capsules are indicated for cholesterol gallstones, cholestatic liver diseases, and bile reflux gastritis. This product can effectively dissolve cholesterol stones and also possesses important properties such as promoting bile secretion, protecting hepatocytes, and modulating the immune system. It has been widely used in the clinical treatment of various liver diseases.
The launch of Yichang Renfu Pharmaceutical’s Ursodeoxycholic Acid Capsules further enriches the company’s product portfolio and strengthens its competitiveness and overall market share in the domestic market. The company will subsequently actively promote the commercialization and sales of this product.
Trending News
Corporate culture
Make drug launches safer and faster, and ensure the tree of life remains evergreen.
Learn moreContact Us
Business customer service
-
Telephone：:+86-027-86506632
Human Resources Department
Address: No.98 shendun 2nd Road, Donghu New Technology Development Zone, Wuhan
Official wechat
Copyright: Wuhan humanwell likang pharmaceutical co.,ltd